Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACACB | O00763 | 1/20 | 0.46 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.45 |
| ▸ | CHRNB4 | P30926 | 1/20 | 0.45 |
| ▸ | CHRNA3 | P32297 | 1/20 | 0.45 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.45 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.45 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.42 |
| ▸ | RECQL | P46063 | 1/20 | 0.42 |
| ▸ | MMP2 | P08253 | 1/20 | 0.40 |
| ▸ | MMP3 | P08254 | 1/20 | 0.40 |
| ▸ | MMP13 | P45452 | 1/20 | 0.40 |
| ▸ | HAO1 | Q9UJM8 | 1/20 | 0.40 |
| ▸ | APP | P05067 | 12/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18290925 | 0.85 | LTA4H (0.50) | ACACBCHRNB2CHRNB4CHRNA3CHRNA7 | |
| SCHEMBL28687083 | 0.84 | HRH3 (0.54) | ACACBMMP2MMP3MMP13APP | |
| SCHEMBL14231797 | 0.83 | KDM4E (0.56) | ACACBCHRNB2CHRNB4CHRNA3CHRNA7 | |
| SCHEMBL14926645 | 0.83 | ACACB (0.50) | ACACBCHRNB2CHRNB4CHRNA3CHRNA7 | |
| SCHEMBL20681007 | 0.83 | HAO1 (0.40) | ACACBCHRNB2CHRNB4CHRNA3CHRNA7 | |
| SCHEMBL14926643 | 0.83 | ACACB (0.50) | ACACBCHRNB2CHRNB4CHRNA3CHRNA7 | |
| SCHEMBL9333010 | 0.83 | CHRNB2 (0.50) | ACACBCHRNB2CHRNB4CHRNA3CHRNA7 | |
| SCHEMBL9335388 | 0.83 | ACACB (0.50) | ACACBCHRNB2CHRNB4CHRNA3CHRNA7 | |
| SCHEMBL14930442 | 0.81 | MCHR1 (0.57) | ACACBMCHR1KDM4EAPP | |
| SCHEMBL10102350 | 0.80 | APP (0.55) | ACACBMCHR1HAO1APP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160031907-A1 | Substituted Benzene Compounds | Epizyme, Inc. | 2016-02-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160031907-A1 | Substituted Benzene Compounds | CYP1B1, CYP4B1, CYP2B6 | ACACB 573/4885CHRNB2 3682/4885CHRNB4 3810/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.